tbuckley/cabot-search huggingface dataset:
Optical genome mapping improves the accuracy of classification, risk stratification, and personalized treatment strategies for patients with acute myeloid leukemia
Authors: Sanam Loghavi, Qing Wei, Farhad Ravandi, Andres E. Quesada, Mark J. Routbort, Shimin Hu, Gokce A. Toruner, Sa A. Wang, Wei Wang, Roberto N. Miranda, Shaoying Li, Jie Xu, Courtney D. DiNardo, Naval Daver, Tapan M. Kadia, Ghayas C. Issa, Hagop M. Kantarjian, L. Jeffrey Medeiros, Guilin Tang
Journal: American Journal of Hematology (2024)

Abstract Cytogenomic characterization is crucial for the classification and risk stratification of acute myeloid leukemia (AML), thereby facilitating therapeutic decision‐making. We examined the clinical utility of optical genome mapping (OGM) in 159 AML patients (103 newly diagnosed and 56 refractory/relapsed), all of whom also underwent chromosomal banding analysis (CBA), fluorescence in situ hybridization, and targeted next‐generation sequencing. OGM detected nearly all clinically relevant cytogenetic abnormalities that SCG identified with &gt;99% sensitivity, provided the clonal burden was above 20%. OGM identified additional cytogenomic aberrations and/or provided information on fusion genes in 77 (48%) patients, including eight patients with normal karyotypes and four with failed karyotyping. The most common additional alterations identified by OGM included chromoanagenesis ( n = 23), KMT2A partial tandem duplication ( n = 11), rearrangements involving MECOM ( n = 7), NUP98 ( n = 2), KMT2A ( n = 2), JAK2 ( n = 2), and other gene fusions in 17 patients, with 10 showing novel fusion gene partners. OGM also pinpointed fusion genes in 17 (11%) patients where chromosomal rearrangements were concurrently detected by OGM and CBA. Overall, 24 (15%) aberrations were identified exclusively by OGM and had the potential to alter AML classification, risk stratification, and/or clinical trial eligibility. OGM emerges as a powerful tool for identifying fusion genes and detecting subtle or cryptic cytogenomic aberrations that may otherwise remain undetectable by CBA.
A metabolic atlas of blood cells in young and aged mice identifies uridine as a metabolite to rejuvenate aged hematopoietic stem cells
Authors: Xiangjun Zeng, Ce Shi, Yingli Han, Kejia Hu, Xiaoqing Li, Cong Wei, Lijuan Ding, Jiazhen Cui, Simao Huang, Yulin Xu, Meng Zhang, Wei Shan, Qian Luo, Jian Yu, Zhongzheng Zheng, Xia Li, Pengxu Qian, He Huang
Journal: Nature Aging (2024)
Integrated analyses highlight interactions between the three-dimensional genome and DNA, RNA and epigenomic alterations in metastatic prostate cancer
Authors: Shuang G Zhao, Matthew Bootsma, Stanley Zhou, Raunak Shrestha, Thaidy Moreno-Rodriguez, Arian Lundberg, Chu Pan, Christopher Arlidge, James R Hawley, Adam Foye, Alana S Weinstein, Martin Sjöström, Meng Zhang, Haolong Li, Lisa N Chesner, Nicholas R Rydzewski, Kyle T Helzer, Yue Shi, Molly Lynch, Scott M Dehm, Joshua M Lang, Joshi J Alumkal, Hansen H He, Alexander W Wyatt, Rahul Aggarwal, Wilbert Zwart, Eric J Small, David A Quigley, Mathieu Lupien, Felix Y Feng
Journal: Nature Genetics (2024)

Abstract The impact of variations in the three-dimensional structure of the genome has been recognized, but solid cancer tissue studies are limited. Here, we performed integrated deep Hi-C sequencing with matched whole-genome sequencing, whole-genome bisulfite sequencing, 5-hydroxymethylcytosine (5hmC) sequencing and RNA sequencing across a cohort of 80 biopsy samples from patients with metastatic castration-resistant prostate cancer. Dramatic differences were present in gene expression, 5-methylcytosine/5hmC methylation and in structural variation versus mutation rate between A and B (open and closed) chromatin compartments. A subset of tumors exhibited depleted regional chromatin contacts at the AR locus, linked to extrachromosomal circular DNA (ecDNA) and worse response to AR signaling inhibitors. We also identified topological subtypes associated with stark differences in methylation structure, gene expression and prognosis. Our data suggested that DNA interactions may predispose to structural variant formation, exemplified by the recurrent TMPRSS2 – ERG fusion. This comprehensive integrated sequencing effort represents a unique clinical tumor resource.
Skeletal Muscle Composition, Power, and Mitochondrial Energetics in Older Men and Women With Knee Osteoarthritis
Authors: Giovanna Distefano, Stephanie Harrison, John Lynch, Thomas M. Link, Philip A. Kramer, Sofhia V. Ramos, Theresa Mau, Paul M. Coen, Lauren M. Sparks, Bret H. Goodpaster, Peggy M. Cawthon, Jane A. Cauley, Nancy E. Lane
Journal: Arthritis & Rheumatology (2024)

Objective Our objective was to investigate the overall and sex‐specific relationships between the presence and severity of knee osteoarthritis (KOA) and muscle composition, power, and energetics in older adults. Methods Male and female patients (n = 655, mean ± SD age 76.1 ± 4.9 years; 57% female) enrolled in the Study of Muscle, Mobility, and Aging completed standing knee radiographs and knee pain assessments. Participants were divided into three groups using Kellgren‐Lawrence grade (KLG) of KOA severity (0–1, 2, or 3–4). Outcome measures included whole‐body muscle mass, thigh fat‐free muscle (FFM) volume and muscle fat infiltration (MFI), leg power, specific power (power normalized to muscle volume), and muscle mitochondrial energetics. Results Overall, the presence and severity of KOA is associated with greater MFI, lower leg power and specific power, and reduced oxidative phosphorylation ( P trend &lt; 0.036). Sex‐specific analysis revealed reduced energetics only in female patients with KOA ( P trend &lt; 0.007) compared to female patients without KOA. In models adjusted for age, sex, race, nonsteroidal anti‐inflammatory drug administration, site or technician, physical activity, height, and participants with abdominal adiposity with KLG 3 to 4 had greater MFI (mean 0.008%, 95% confidence interval [CI] 0.004%–0.011%) and lower leg power (mean −51.56 W, 95% CI −74.03 to −29.10 W) and specific power (mean −5.38 W/L, 95% CI −7.31 to −3.45 W/L) than those with KLG 0 to 1. No interactions were found between pain and KLG status. Among those with KOA, MFI and oxidative phosphorylation were associated with thigh FFM volume, leg power, and specific power. Conclusion Muscle health is associated with the presence and severity of KOA and differs by sex. Although muscle composition and power are lower in both male and female patients with KOA, regardless of pain status, mitochondrial energetics is reduced only in female patients.
Frontline therapy of acute myeloid leukemia with lower intensity regimens: Where are we now and where can we go?
Authors: Jennifer Marvin‐Peek, Jason S. Gilbert, Daniel A. Pollyea, Courtney D. DiNardo
Journal: American Journal of Hematology (2024)

Abstract The advent of molecularly targeted therapeutics has transformed the management of patients with acute myeloid leukemia (AML). Particularly for individuals unfit for intensive chemotherapy, lower intensity therapies (LIT) incorporating small molecules have significantly improved patient outcomes. With BCL2, IDH1, IDH2, and FLT3 inhibitors widely used for relapsed AML, combination regimens are now utilized in the frontline. Expansion of these targeted LIT combinations, along with development of novel agents including menin inhibitors, exemplifies the promise of precision medicine. Further understanding of molecular drivers of leukemic transformation and mechanisms of relapse will continue to advance frontline treatment options for patients with AML.
Central nervous system efficacy of aumolertinib versus gefitinib in patients with untreated, <i>EGFR</i>‐mutated, advanced non‐small cell lung cancer: data from a randomized phase III trial (AENEAS)
Authors: Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Dongqing Lv, Guojun Zhang, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui, Xingxiang Xu, Jian Fang, Jifeng Feng, Zhi Xu, Rui Ma, Jie Hu, Nong Yang, Xiangdong Zhou, Xiaohong Wu, Chengping Hu, Zhihong Zhang, You Lu, Yanping Hu, Liyan Jiang, Qiming wang, Renhua Guo, Jianying Zhou, Baolan Li, Chunhong Hu, Wancheng Tong, Helong Zhang, Lin Ma, Yuan Chen, Zhijun Jie, Yu Yao, Longzhen Zhang, Jie Weng, Weidong Li, Jianping Xiong, Xianwei Ye, Jianchun Duan, Haihua Yang, Meili Sun, Hongying Wei, Jiawei Wei, Zheyu Zhang, Qiong Wu
Journal: Cancer Communications (2024)

The initial randomized, double-blinded, actively controlled, phase III ANEAS study (NCT03849768) demonstrated that aumolertinib showed superior efficacy relative to gefitinib as first-line therapy in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer (NSCLC). Metastatic disease in the central nervous system (CNS) remains a challenge in the management of NSCLC. This study aimed to compare the efficacy of aumolertinib versus gefitinib among patients with baseline CNS metastases in the ANEAS study.
Real‐world data on ALK rearrangement test in Chinese advanced non‐small cell lung cancer (RATICAL): a nationwide multicenter retrospective study
Authors: Lin Li, Wencai Li, Chunyan Wu, Yanfeng Xi, Lei Guo, Yuan Ji, Lili Jiang, Ji Li, Jingping Yun, Gang Chen, Yuan Li, Yueping Liu, Dianbin Mu, Yuchen Han, Leina Sun, Qingxin Xia, Xiaodong Teng, Nanying Che, Wei Wu, Xueshan Qiu, Chao Liu, Xiaochu Yan, Daiqiang Li, Zhihong Zhang, Zhe Wang, Yujun Li, Zheng Wang, Lingchuan Guo, Xiu Nie, Jingshu Geng, Jianhua Zhou, Jianming Ying
Journal: Cancer Communications (2024)

Abstract Background Anaplastic lymphoma kinase ( ALK ) test in advanced non‐small cell lung cancer (NSCLC) can help physicians provide target therapies for patients harboring ALK gene rearrangement. This study aimed to investigate the real‐world test patterns and positive rates of ALK gene rearrangements in advanced NSCLC. Methods In this real‐world study (ChiCTR2000030266), patients with advanced NSCLC who underwent an ALK rearrangement test in 30 medical centers in China between October 1, 2018 and December 31, 2019 were retrospectively analyzed. Interpretation training was conducted before the study was initiated. Quality controls were performed at participating centers using immunohistochemistry (IHC)‐VENTANA‐D5F3. The positive ALK gene rearrangement rate and consistency rate were calculated. The associated clinicopathological characteristics of ALK gene rearrangement were investigated as well. Results The overall ALK gene rearrangement rate was 6.7% in 23,689 patients with advanced NSCLC and 8.2% in 17,436 patients with advanced lung adenocarcinoma. The quality control analysis of IHC‐VENTANA‐D5F3 revealed an intra‐hospital consistency rate of 98.2% (879/895) and an inter‐hospital consistency rate of 99.2% (646/651). IHC‐VENTANA‐D5F3 was used in 53.6%, real‐time polymerase chain reaction (RT‐PCR) in 25.4%, next‐generation sequencing (NGS) in 18.3%, and fluorescence in‐situ hybridization (FISH) in 15.9% in the adenocarcinoma subgroup. For specimens tested with multiple methods, the consistency rates confirmed by IHC‐VENTANA‐D5F3 were 98.0% (822/839) for FISH, 98.7% (1,222/1,238) for NGS, and 91.3% (146/160) for RT‐PCR. The overall ALK gene rearrangement rates were higher in females, patients of ≤ 35 years old, never smokers, tumor cellularity of &gt; 50, and metastatic specimens used for testing in the total NSCLC population and adenocarcinoma subgroup (all P &lt; 0.05). Conclusions This study highlights the real‐world variability and challenges of ALK test in advanced NSCLC, demonstrating a predominant use of IHC‐VENTANA‐D5F3 with high consistency and distinct clinicopathological features in ALK ‐positive patients. These findings underscore the need for a consensus on optimal test practices and support the development of refined ALK test strategies to enhance diagnostic accuracy and therapeutic decision‐making in NSCLC.
Effects of dapagliflozin according to <scp>QRS</scp> duration across the spectrum of left ventricular ejection fraction: An analysis of <scp>DAPA</scp>‐<scp>HF</scp> and <scp>DELIVER</scp>
Authors: Amr Abdin, Toru Kondo, Michael Böhm, Pardeep S. Jhund, Brian L. Claggett, Muthiah Vaduganathan, Adrian F. Hernandez, Carolyn S.P. Lam, Silvio E. Inzucchi, Felipe A. Martinez, Rudolf A. de Boer, Akshay S. Desai, Lars Køber, Marc S. Sabatine, Magnus Petersson, Erasmus Bachus, Scott D. Solomon, John J.V. McMurray
Journal: European Journal of Heart Failure (2024)

Abstract Aims The primary aim was to evaluate the effect of dapagliflozin according to QRS duration across the spectrum of left ventricular ejection fraction (LVEF), given that prolongation of QRS duration is associated with less favourable ventricular remodelling with pharmacological therapy and worse outcomes. Methods and results A pooled analysis of the DAPA‐HF and DELIVER trials, excluding patients with a paced rhythm and cardiac resynchronization therapy. Overall, 4008 patients had heart failure (HF) with reduced ejection fraction (HFrEF), and 5816 had HF with mildly reduced/preserved ejection fraction (HFmrEF/HFpEF). QRS duration was &lt;120 ms in 7039 patients (71.7%), 120–149 ms in 1725 (17.6%), and ≥150 ms in 1060 patients (10.8%). The median follow‐up time was 23 months. The rate of the primary composite outcome of cardiovascular death or worsening HF was 9.2 (95% confidence interval [CI] 8.7–9.7), 14.3 (13.0–15.7), and 15.9 (14.1–17.9) per 100 patient‐years in the &lt;120, 120–149, and ≥150 ms groups, respectively. This gradient in event rates was observed both in HFrEF and HFmrEF/HFpEF. Dapagliflozin, compared with placebo, reduced the risk of the primary outcome consistently across the QRS duration subgroups (hazard ratio [95% CI] 0.75 [0.67–0.85], 0.79 [0.65–0.96], and 0.89 [0.70–1.13] in the &lt;120, 120–149, and ≥150 ms groups, respectively; p for interaction = 0.28). The effect of dapagliflozin on the primary outcome was consistent across the QRS duration regardless of HF phenotype that is, HFrEF or HFmrEF/HFpEF. Conclusions Prolongation of QRS duration is associated with worse outcomes irrespective of HF phenotype. Dapagliflozin reduced the risk of the primary outcome, regardless of QRS duration, in DAPA‐HF and DELIVER.
Pulmonary herpes simplex virus and cytomegalovirus in patients with acute respiratory distress syndrome related to COVID-19
Authors: Leonoor S. Boers, Frank van Someren Gréve, Jarne M. van Hattem, Justin de Brabander, Tom Zwaan, Hugo van Willigen, Marion Cornelissen, Menno de Jong, Tom van der Poll, JanWillem Duitman, Janke Schinkel, Lieuwe D. J. Bos, Paul E. Verweij, Simone J. C. F. M. Moorlag, Frank L. van de Veerdonk, Lieuwe D. J. Bos, Frank van Someren Grevé, Jeroen J. A. van Kampen, Joost Wauters, Katrien Lagrou, Simon Feys, Jannes Heylen, Michiel van Agtmael, Anne Geke Algera, Brent Appelman, Floor van Baarle, Diederik van de Beek, Martijn Beudel, Harm Jan Bogaard, Lieuwe Bos, Michela Botta, Godelieve de Bree, Matthijs C. Brouwer, Sanne de Bruin, Marianna Bugiani, Esther Bulle, David T. P. Buis, Osoul Chouchane, Alex Cloherty, Mirjam Dijkstra, Dave A. Dongelmans, Romein W. G. Dujardin, Paul Elbers, Lucas Fleuren, Suzanne Geerlings, Theo Geijtenbeek, Armand Girbes, Bram Goorhuis, Martin P. Grobusch, Laura Hagens, Jorg Hamann, Vanessa Harris, Robert Hemke, Sabine M. Hermans, Leo Heunks, Markus Hollmann, Janneke Horn, Joppe W. Hovius, Menno D. de Jong, Rutger Koning, Endry H. T. Lim, Niels van Mourik, Jeaninne Nellen, Esther J. Nossent, Frederique Paulus, Edgar Peters, Dan A. I. Piña-Fuentes, Bennedikt Preckel, Jorinde Raasveld, Tom Reijnders, Maurits C. F. J. de Rotte, Michiel Schinkel, Marcus J. Schultz, Femke A. P. Schrauwen, Alex Schuurman, Jaap Schuurmans, Kim Sigaloff, Marleen A. Slim, Patrick Smeele, Marry Smit, Cornelis S. Stijnis, Willemke Stilma, Charlotte Teunissen, Patrick Thoral, Anissa M. Tsonas, Pieter R. Tuinman, Marc van der Valk, Denise Veelo, Alexander P. J. Vlaar, Carolien Volleman, Heder de Vries, Lonneke A. Vught, Michèle van Vugt, W. Joost Wiersinga, Dorien Wouters, A. H. Zwinderman, Matthijs C. Brouwer. E. J. Nossent, J. W. Duitman, A. Saris, H. de Vries, L. J. Meijboom, L. D. J. Bos, S. G. Blok, A. R. Schuurman, T. D. Y. Reijnders, J. J. Garcia Vallejo, H. Bontkes, A. P. J. Vlaar, W. J. Wiersinga, R. Lutter, T. van der Poll, H. J. Bogaard, L. Heunks, S. Zhang, R. F. J. Kullberg, J. de Brabander, L. S. Boers
Journal: Intensive Care Medicine (2024)

Human herpesviruses, particularly cytomegalovirus (CMV) and herpes simplex virus (HSV), frequently reactivate in critically ill patients, including those with acute respiratory distress syndrome (ARDS) related to coronavirus disease 2019 (COVID-19). The clinical interpretation of pulmonary herpesvirus reactivation is challenging and there is ongoing debate about its association with mortality and benefit of antiviral medication. We aimed to quantify the incidence and pathogenicity of pulmonary CMV and HSV reactivations in critically ill COVID-19 patients.
Maternal Diet and Gut Microbiota Influence Predisposition to Cardiovascular Disease in Offspring
Authors: Hamdi A. Jama, Malathi S.I. Dona, Evany Dinakis, Michael Nakai, Madeleine R. Paterson, Waled A. Shihata, Crisdion Krstevski, Charles D. Cohen, Kate L. Weeks, Gabriella E. Farrugia, Chad Johnson, Ekaterina Salimova, Daniel G. Donner, Helen Kiriazis, Harikrishnan Kaipananickal, Jun Okabe, Dovile Anderson, Darren J. Creek, Charles R. Mackay, Assam El-Osta, Alexander R. Pinto, David M. Kaye, Francine Z. Marques
Journal: Circulation Research (2024)
Effectiveness of a group psychological intervention to reduce psychosocial distress in adolescents in Pakistan: a single-blind, cluster randomised controlled trial
Authors: Syed Usman Hamdani, Zill-e Huma, Aiysha Malik, Asad Tamizuddin-Nizami, Hashim Javed, Fareed Aslam Minhas, Mark J D Jordans, Marit Sijbrandij, Nadia Suleman, Um-ul Baneen, Richard Allan Bryant, Mark van Ommeren, Atif Rahman, Duolao Wang
Journal: The Lancet Child & Adolescent Health (2024)
A community case detection tool to promote help-seeking for mental health care among children and adolescents in Ugandan refugee settlements: a stepped wedge cluster randomised trial
Authors: Myrthe van den Broek, Sandra Agondeze, M Claire Greene, Rosco Kasujja, Anthony F Guevara, Racheal Kisakye Tukahiirwa, Brandon A Kohrt, Mark J D Jordans
Journal: The Lancet Child & Adolescent Health (2024)
Association of baseline and longitudinal changes in insulin‐like growth factor‐binding protein‐7 with the risk of incident heart failure: Data from the PREVEND study
Authors: Sabrina Abou Kamar, Valentina Bracun, Maissa El‐Qendouci, Nils Bomer, Stephan J.L. Bakker, Ron T. Gansevoort, Eric Boersma, Isabella Kardys, Rudolf A. de Boer, Navin Suthahar
Journal: European Journal of Heart Failure (2024)

Senescence is a major risk factor for heart failure (HF), and insulin-like growth factor-binding protein-7 (IGFBP7) has been identified as an important senescence-inducing factor. The aim of this study was to examine the value of baseline and repeat IGFBP7 measurements in predicting future HF among community-dwelling Dutch adults from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study.
Precision Culture Scaling to Establish High‐Throughput Vasculogenesis Models (Adv. Healthcare Mater. 18/2024)
Authors: Nicholas R. Dennison, Maximilian Fusenig, Lisa Grönnert, Manfred F. Maitz, Maria Alejandra Ramirez Martinez, Manja Wobus, Uwe Freudenberg, Martin Bornhäuser, Jens Friedrichs, Peter D. Westenskow, Carsten Werner
Journal: Advanced Healthcare Materials (2024)
Antimicrobial Peptide‐ and Dentin Matrix‐Functionalized Hydrogel for Vital Pulp Therapy via Synergistic Bacteriostasis, Immunomodulation, and Dentinogenesis (Adv. Healthcare Mater. 18/2024)
Authors: Zhuo Xie, Wentao Jiang, Hui Liu, Lingling Chen, Chengkai Xuan, Zhenxing Wang, Xuetao Shi, Zhengmei Lin, Xianling Gao
Journal: Advanced Healthcare Materials (2024)
A Nanoreactor Based on Metal–Organic Frameworks With Triple Synergistic Therapy for Hepatocellular Carcinoma
Authors: Heming Zheng, Lei Huang, Guanghui An, Lianshan Guo, Nannan Wang, Wenhui Yang, Yanqiu Zhu
Journal: Advanced Healthcare Materials (2024)

The transformation of monotherapy into multimodal combined targeted therapy to fully exploit synergistic efficacy is of increasing interest in tumor treatment. In this work, a novel nanodrug-carrying platform based on iron-based MOFs, which is loaded with doxorubicin hydrochloride (DOX), dihydroartemisinin (DHA), and glucose oxidase (GOx), and concurrently covalently linked to the photosensitizer 5,10,15,20-tetrakis(4-carboxyphenyl)porphyrin (TCPP) in polydopamine (PDA)-encapsulated MIL-101(Fe) (denoted as MIL-101(Fe)-DOX-DHA@TCPP/GOx@PDA, MDDTG@P), is successfully developed. Upon entering the tumor microenvironment, MDDTG@P catalyzes the hydrogen peroxide (H
Fine‐Tuning Electron Transfer for Nanozyme Design
Authors: Xia Zong, Xinran Xu, Dai‐Wen Pang, Xinglu Huang, An‐An Liu
Journal: Advanced Healthcare Materials (2024)

Nanozymes, with their versatile composition and structural adaptability, present distinct advantages over natural enzymes including heightened stability, customizable catalytic activity, cost-effectiveness, and simplified synthesis process, making them as promising alternatives in various applications. Recent advancements in nanozyme research have shifted focus from serendipitous discovery toward a more systematic approach, leveraging machine learning, theoretical calculations, and mechanistic explorations to engineer nanomaterial structures with tailored catalytic functions. Despite its pivotal role, electron transfer, a fundamental process in catalysis, has often been overlooked in previous reviews. This review comprehensively summarizes recent strategies for modulating electron transfer processes to fine-tune the catalytic activity and specificity of nanozymes, including electron-hole separation and carrier transfer. Furthermore, the bioapplications of these engineered nanozymes, including antimicrobial treatments, cancer therapy, and biosensing are also introduced. Ultimately, this review aims to offer invaluable insights for the design and synthesis of nanozymes with enhanced performance, thereby advancing the field of nanozyme research.
Oxygen‐Vacancy‐Rich Monolayer BiO<sub>2−</sub><i><sub>X</sub></i> Nanosheets for Bacterial Sepsis Management via Dual Physically Antibacterial and Chemically Anti‐inflammatory Functions (Adv. Healthcare Mater. 18/2024)
Authors: Fang Liu, Kun Zhang, Bin Lu, Xiaochun Wang, Qingrong Dong, Tingyu Xue, Yan Tan, Xing Wang, Jiangfeng Du
Journal: Advanced Healthcare Materials (2024)
Label‐Free Single Microparticles and Cell Aggregates Sorting in Continuous Cell‐Based Manufacturing (Adv. Healthcare Mater. 18/2024)
Authors: Lingyan Gong, Linwei He, Nan Lu, Chayakorn Petchakup, King Ho Holden Li, Chor Yong Tay, Han Wei Hou
Journal: Advanced Healthcare Materials (2024)
Micro‐Engineered Heart Tissues On‐Chip with Heterotypic Cell Composition Display Self‐Organization and Improved Cardiac Function (Adv. Healthcare Mater. 18/2024)
Authors: Carla Cofiño‐Fabres, Tom Boonen, José M. Rivera‐Arbeláez, Minke Rijpkema, Lisanne Blauw, Patrick C. N. Rensen, Verena Schwach, Marcelo C. Ribeiro, Robert Passier
Journal: Advanced Healthcare Materials (2024)